Neu­rona rais­es $120M to take epilep­sy cell ther­a­py to late-stage de­vel­op­ment

Neu­rona Ther­a­peu­tics has gath­ered $120 mil­lion in what is ex­pect­ed to be its last pri­vate fi­nanc­ing round to wrap up an open-la­bel study this year and move its epilep­sy cell ther­a­py in­to a ran­dom­ized Phase II in 2025, CEO and co-founder Cory Nicholas told End­points News.

The fi­nanc­ing brings the nine-year-old biotech’s to­tal cap­i­tal haul to date to about $285 mil­lion, Nicholas said, not­ing Neu­rona will as­sess mar­ket con­di­tions about an ini­tial pub­lic of­fer­ing as its next fi­nanc­ing step.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER